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Abstract
In observational studies, vitamin D deficiency is associated with depressive symptoms. However, randomised controlled trials (RCT) with vitamin D sup-
plementation have not been conclusive. In the present study 206 subjects were randomised to vitamin D (100 000 IU (2500 µg) as a bolus dose followed by
20 000 IU (500 µg) per week) and 202 to placebo. The Beck Depression Inventory-II (BDI-II) was filled in at baseline and after 4 months at the end of the
study. At baseline the mean age was 51·4 and 52·5 years and mean serum 25-hydroxyvitamin D (25(OH)D) 32·5 and 35·1 nmol/l in the vitamin D and
placebo groups, respectively. Among the 408 subjects, 193 had a BDI-II score >4, and forty-five had a score >13. Twenty-three subjects were using anti-
depressant or mood-stabilising drugs. At the end of the study, there were no significant differences in Δ BDI-II score (score at the end of the study minus
score at baseline), regardless of analysing all subjects, subjects with or without psycopharmaca, or if performing subgroup analyses based on baseline and
final serum 25(OH)D levels combined with categories of baseline BDI-II scores >4 or >13. In conclusion, we have not been able to demonstrate any
significant effect of vitamin D supplementation on depressive symptoms. However, few of our subjects were clinically depressed. Future RCT should
include subjects with more severe vitamin D deficiency as well as more depressed subjects than in our study. In such a setting vitamin D may probably
be more relevant as an augmenter of standard antidepressant medication/treatment.
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Vitamin D is essential for Ca metabolism and bone health(1),
but may also be important for brain development and func-
tion(2–4). This is reasonable, since vitamin D metabolites
may cross the blood–brain barrier(5), and the vitamin D recep-
tor as well as the enzymes necessary for the activation of vita-
min D to its active form 1,25-dihydroxyvitamin D are present
in the central nervous system(6,7). Furthermore, vitamin D
deficiency has been associated with impaired cognitive func-
tion and psychiatric symptoms like depression in several obser-
vational studies(8,9). However, it has been difficult to
demonstrate a causal relationship between vitamin D defi-
ciency and depression.
Since sun-induced production of vitamin D in the skin is
the main vitamin D source(1), the low levels of serum
25-hydroxyvitamin D (25(OH)D), which is used as a marker
of vitamin D status(1), could be the result and not the cause
of depression. The only way to settle this question is through
properly performed randomised controlled trials (RCT), but
the results of those performed so far are not conclusive(10–15).
One reason for the apparent lack of effect of vitamin D sup-
plementation could be that the subjects included were not vita-
min D insufficient (serum 25(OH)D < 50 nmol/l)(16) and,
accordingly, no benefit from additional vitamin D was to be
expected. Thus, in the nine RCT that met the inclusion criteria
Abbreviations: 25(OH)D, 25-hydroxyvitamin D; BDI-II, Beck Depression Inventory-II; PTH, parathyroid hormone; RCT, randomised controlled trial.
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for meta-analysis by Gowda et al.(13) on vitamin D supplemen-
tation to reduce depression in adults published in 2015, only
two RCT had mean baseline serum 25(OH)D below 50
nmol/l. Furthermore, the mean serum 25(OH)D levels in
these two studies were as high as 45 and 47 nmol/l(17,18),
and the effect of vitamin D deficiency on depressive symp-
toms was therefore not truly tested.
In Tromsø, Northern Norway, large population-based
health surveys are performed at 6- to 8-year intervals(19).
The seventh was conducted in 2015/2016 and included
serum 25(OH)D measurements in more than 20 000 subjects.
We were therefore able to invite a large number of subjects
with low serum 25(OH)D levels in an RCT on vitamin D
and depressive symptoms. Our main hypothesis was that sup-
plementation with vitamin D would improve depressive symp-
toms as evaluated with the Beck Depression Inventory-II
(BDI-II). Furthermore, we wanted to perform subgroup ana-
lyses in the subjects with low baseline vitamin 25(OH)D levels
and with high BDI-II scores since these were the subjects
where an effect of vitamin D supplementation most likely
would be seen.
Methods
Subjects and study design
The main endpoint in the vitamin D intervention study was
cardiovascular risk factors, and the design of the study and
the main endpoint results have been reported in detail(20). In
short, the subjects were recruited from the Tromsø Study,
which is a population-based health survey in the municipality
of Tromsø in northern Norway at 69° north(19). The seventh
survey was performed in 2015/2016 and all citizens aged 40
years and above (n 32 591) were invited, 21 083 attended,
serum 25(OH)D successfully measured in 20 922, and 1489
subjects with serum values <42 nmol/l and with age <80
years invited by mail to participate in the present study. The
cut-off of 42 nmol/l was chosen as this was estimated to result
in a sufficient number of subjects with vitamin D insufficiency
where an effect of vitamin D supplementation could be
expected(8). A total of 698 subjects responded and 639 were
screened by telephone for the following exclusion criteria:
known granulomatous disease, diabetes, renal stones in the
last 5 years, serious diseases making the subject unfit for par-
ticipation, use of vitamin D supplements >800 IU (20 µg) vita-
min D per d, use of solarium on a regular basis, and planned
holiday(s) in tropical areas during the study period. Women of
childbearing potential without use of acceptable contraception
were excluded.
A total of 455subjects passed this initial telephone screening
and attended the first visit at the Clinical Research Unit at the
University Hospital of North Norway where the informed
consent form was signed, clinical examinations performed,
medical history taken and blood samples drawn. These exam-
inations did not reveal any contraindication for participation in
422 subjects who then attended the next visit within 2–5 d. At
this second (non-fasting) visit, the BDI-II was filled in and the
study drugs (Dekristol cholecalciferol capsules (20 000 IU;
500 µg); Mibe GmbH) or identical-looking placebo capsules
containing arachis oil (Ayanda GmbH & Co. KG) were dis-
pensed. Five capsules were given as a loading dose followed
by one capsule each week.
The randomisation was stratified according to sex, vitamin
D status in the Tromsø Study (above/below 25 nmol/l),
smoking status (current smoker yes/no) and BMI above/
below 27 kg/m2. All nurses, doctors, other study personnel
and study participants were blinded throughout the study.
The subjects were asked not to take any vitamin D supple-
ments (including cod liver oil) during the intervention period.
After 4 months the third and fourth visits were performed,
identical to the first and the second. Unused medication was
returned and counted. Compliance was calculated as the
ratio between capsules used (capsules supplied minus capsules
returned) and number of weeks between the second and
fourth visits. In all, 411 subjects attended the last visit.
Among these, 408 subjects (206 given vitamin D and 202 pla-
cebo) had complete BDI-II scores both at baseline and at the
end of the study and were included in the analyses.
Measurements
The subjects were asked regarding anti-depressant or
mood-stabilising drugs (psychopharmaca), and classified as
users/non-users of psychopharmaca. Height and weight
were measured wearing light clothing without shoes and
BMI calculated as weight (kg) divided by height squared
(m2). Serum Ca (mmol/l) was analysed by using the Hitachi
917 (Roche Diagnostics), with reagents from Boehringer-
Mannheim. Serum parathyroid hormone (PTH) level
(pmol/l) was measured using an Immulite 2000 Intact PTH
analyser (Siemens Healthcare Diagnostics). Serum 25(OH)D
(nmol/l) was measured with an in-house liquid chromatog-
raphy–tandem MS method that detects both 25(OH)D3 and
25(OH)D2 and the sum of these is presented as 25(OH)D
in the results. The assay has a between-day CV of <9 %,
and a within-day CV of < 2 %(21).
The BDI-II questionnaire consists of twenty-one items,
each with four statements(22). The subjects are asked to choose
the statement that best describes their condition during the last
2 weeks. The statements are rated from 0 (normal or least
depressed mood) to 3 (most depressed mood). The BDI-II
score was obtained by adding all the values together. A
score 0–13 is considered as none or minimal depression,
14–19 as mild depression, 20–28 as moderate depression
and 29–63 as severe depression(23). The BDI-II score varies
considerably between populations, with mean scores of
about 9 and medians of 6–7 in most non-clinical samples(24,25).
Statistical analyses
Normal distribution was evaluated with skewness and kurtosis
and visual inspection of histograms and found normal for all
parameters except the BDI-II scores at baseline and at the
end of the study. However, the Δ BDI-II scores (value at




























































































































Correlations were evaluated at baseline with Spearman’s rho.
Comparisons between groups (men/women, smokers/non-
smokers, users/non-users of psychopharmaca, and the vita-
min D/placebo groups) at baseline were performed with
Student’s t test, χ2 test or the Mann–Whitney U test.
Comparisons between baseline and end of study values
within the vitamin D and placebo groups were performed
with Student’s t test or the Mann–Whitney U test.
Comparisons between the vitamin D and placebo groups at
the end of the study were performed with a general linear
model with value at the end of the study as the dependent vari-
able, sex and randomisation status as fixed factors, and age
and baseline value as covariates(26). For the BDI-II score the
Δ values (which were normally distributed) were used as
dependent variables in this analysis. The distribution of the
BDI-II scores at the end of the study across categories of
end of study serum 25(OH)D (<25, 25–49, 50–74, and
>74 nmol/l) was evaluated with the Kruskal–Wallis test.
P< 0·05 (two-tailed) was considered statically significant.
Data are presented as means and standard deviations or as
medians and ranges. All statistical analyses were performed
using IBM SPSS version 22 software.
Power calculation
For the main endpoint of the study, cardiovascular risk factors
(systolic blood pressure, serum LDL-cholesterol, insulin resist-
ance (by homeostatic model assessment; HOMA)), a total
number of 450 subjects was needed if wanting a power of
0·8 and P < 0·05(20). For depression, the BDI scores were
not normally distributed, and a formal power calculation was
therefore not performed. We have in a previous vitamin D
intervention study in 441 subjects with mean serum 25(OH)
D of 52·5 nmol/l found a slight but significant improvement
after vitamin D supplementation as compared with placebo(27).
In the present study we aimed to include a similar number of
subjects but with substantially lower serum 25(OH)D levels.
Assuming that an effect of vitamin D supplementation
would be more pronounced in vitamin D-insufficient subjects,
450 subjects were considered to give the study reasonable
power. However, we have now performed a post hoc calculation
using the normally distributed Δ BDI-II values. Assuming a
standard deviation for the Δ BDI-II score of 4·3, a power
of 0·8 and P< 0·05, 408 included subjects should be sufficient
to detect a difference in Δ BDI-II of 1·2 between the two
groups.
Ethics
The study was approved by the Regional Committee for
Medical Research Ethics (REK NORD 2013/1464) and by
the Norwegian Medicines Agency (2013-003514-40). The
study is registered at ClinicalTrials.gov (NCT02750293). All
subjects gave their written informed consent.
Results
The baseline characteristics of the 408 subjects included in the
analyses are shown in Table 1. There were no significant cor-
relations between BDI-II score and age, BMI, serum Ca, PTH
or 25(OH)D at baseline, nor were there significant differences
between men and women, smokers and non-smokers regard-
ing BDI-II (data not shown). Subjects using psychopharmaca
(n 23) had significantly lower mean serum 25(OH)D levels
than subjects not using psychopharmaca (n 385) (28·9 (SD
9·6) nmol/l v. 34·1 (SD 12·6) nmol/l; P < 0·05), and they
also had significantly higher median BDI-II scores (11
(range 1–23) v. 4 (range 0–25); P < 0·001) (Table 1, Figs 1
and 2).
At baseline there were no significant differences between the
vitamin D and placebo groups, except for the mean serum 25
(OH)D level which was slightly lower in the vitamin D group
than the placebo group (32·5 (SD 11·1) nmol/l v. 35·1 (SD
13·6) nmol/l; P < 0·05) (Table 2). Inclusion in relation to sea-
son was also similar in the two groups, with most of the
Table 1. Baseline characteristics of all subjects and in those without or with the use of psychopharmaca
(Mean values and standard deviations, numbers of subjects, percentages; medians and ranges)





Mean SD Mean SD Mean SD
Age (years) 52·0 8·8 52·0 8·6 52·0 10·0
Sex (n)
Males 217 205 12
Females 191 180 11
Current smokers (%) 22·1 21·0 39·1*
BMI at baseline (kg/m2) 27·8 4·8 27·8 4·8 28·0 4·8
Serum Ca at baseline (mmol/l) 2·27 0·07 2·27 0·07 2·28 0·07
Serum PTH at baseline (pmol/l) 6·7 2·0 6·7 2·0 6·8 2·2
Serum 25(OH)D at baseline (nmol/l) 33·8 12·5 34·1 12·6 28·9† 9·6
BDI-II score at baseline§ 4 0–25 4 0–25 11‡ 1–23
PTH, parathyroid hormone; 25(OH)D, 25-hydroxyvitamin D; BDI-II, Beck Depression Inventory-II.
* Proportion was significantly different from that of subjects not using psychopharmaca (P < 0·05; χ2 test).
†Mean value was significantly different from that of subjects not using psychopharmaca (P < 0·05; Student’s t test).
‡Median value was significantly different from that of subjects not using psychopharmaca (P < 0·001; Mann–Whitney U test).



























































































































subjects included during the winter months (Supplementary
Figs S1 and S2).
At the end of the study there was an increase in serum 25
(OH)D of about 56 nmol/l in the vitamin D group and a
decrease in the placebo group of about 4 nmol/l; the serum
Ca level was significantly higher and the serum PTH signifi-
cantly lower in the vitamin D group than the placebo group
(Table 2).
In both the vitamin D and placebo groups the final BDI-II
scores were significantly lower than the baseline scores (P<
0·05). However, the Δ BDI-II scores did not differ signifi-
cantly between the vitamin D and placebo group, both when
including all subjects and when analysing users and non-users
of psychopharmaca separately (Table 2 and Fig. 3).
To test our hypothesis that an effect of vitamin D supple-
mentation would most likely be seen in subjects with low base-
line vitamin 25(OH)D levels and with high BDI-II scores,
subgroup analyses were performed. Thus, subjects with base-
line serum 25(OH)D < 50/40/30 nmol/l combined with final
serum 25(OH)D value >70 nmol/l in the vitamin D group,
and baseline and final serum 25(OH)D < 50/40/30 nmol/l
in the placebo group were analysed separately. However, this
did not disclose significant differences in Δ BDI-II regardless
of if inclusion was additionally restricted to subjects with
BDI-II scores >4 or >13 at baseline (Table 3).
Furthermore, when taking all the 408 subjects together,
there were no correlations at the end of the study between Δ
BDI-II score and Δ 25(OH)D; nor were there any significant
trend for BDI-II score across categories of final serum 25
(OH)D values of 0–24 nmol/l (n 57), 25–49 nmol/l (n 139),
50–74 nmol/l (n 52), and >74 nmol/l (n 160) (data not
shown).
No serious study-related side effects were recorded. Two
subjects developed hypercalcaemia (serum Ca = 2·57
mmol/l); one male whose serum Ca normalised upon retest-
ing, and one female who was found to have developed primary
hyperparathyroidism. The compliance rate in the study was
very high; 14 % of the subjects had a compliance rate between
84 and 100 %, and the rest a compliance rate of 100 %.
Discussion
In the present study we found both in the vitamin D and pla-
cebo groups a significant reduction in depressive symptoms as
evaluated by the BDI-II score. However, when comparing the
changes in the two groups, no significant effect of the vitamin
D supplementation on the BDI-II score was found, even if
restricting the analyses to subjects with low serum 25(OH)D
levels and mild depression. The reduction in the BDI-II scores
from baseline in both groups therefore probably reflects an
effect of repeated testing(28).
We have in two previous studies showed slight, but signifi-
cant, effects of vitamin D supplementation on depressive
symptoms. Thus, in a study on 441 overweight subjects with
a mean baseline serum 25(OH)D level of 53 nmol/l, we
found a relationship between baseline serum 25(OH)D and
BDI score, and a positive effect on BDI in those given vitamin
D over a 1-year period as compared with placebo(27). In the
other study, that included 243 subjects with a mean baseline
serum 25(OH)D level of 47 nmol/l, the effect was only seen
in post hoc analyses on those with high BDI score at baseline,
and in only one out of the four depression tests employed(18).
In view of our present finding, we do consider our previous
reports of positive vitamin D effects on depression as due
to chance.
Several meta-analyses and reviews on vitamin D and depres-
sion have been published, and there is a general agreement that
in observational studies there is an association between vitamin
D deficiency and depressive symptoms(10–15). However, for
intervention studies, there appears to be no clear-cut effect,
and many of these studies have been of low quality. Thus,
in a systematic review by Spedding(12) it was reported that
out of fifteen RCT included, eight had obvious biological
flaws and were not properly designed. This was confirmed
in the latest meta-analysis on the topic that included nine
RCT with 4923 participants(13). In none of these nine trials
was the mean baseline serum 25(OH)D level below 40
nmol/l, and in only one, where the mean baseline serum 25
Fig. 1. Frequency of Beck Depression Inventory-II (BDI-II) scores at baseline
in the 385 subjects not using anti-depressant or mood-stabilising drugs.
Fig. 2. Frequency of Beck Depression Inventory-II (BDI-II) scores at baseline



























































































































(OH)D level was 58 nmol/l and the randomisation procedure
unclear(13), were the participant recruited on the basis of clin-
ical depression(29). The conclusion of that meta-analysis was
therefore no surprise: no significant reduction in depression
after vitamin D supplementation. It was also recommended
that future RCT should be performed among individuals
who are both depressed and vitamin D deficient(13).
In our study we aimed at recruiting the subjects with the
lowest serum 25(OH)D levels measured in a population-based
health survey (the Tromsø Study) that included more than 20
000 subjects. All the 408 subjects included had a serum 25
(OH)D value <42 nmol/l in the Tromsø Study, but since
the intervention started up to 4 months later for some of
the subjects, not all were vitamin D insufficient (serum 25
(OH)D < 50 nmol/l) at baseline. However, in the vitamin D
group 163 subjects had baseline serum 25(OH)D < 50
nmol/l and with final serum 25(OH)D > 70 nmol/l (as an
indication of adequate effect of the supplementation), and
Table 2. Baseline and end of study values in all subjects and in those without or with the use of psychopharmaca




















Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD
Age (years) 51·4 8·6 52·5 8·7 51·3 8·4 52·6 8·8 53·0 10·9 50·3 8·8
Sex (n)
Males 109 108 102 103 7 5
Females 97 94 90 90 7 4
BMI at baseline (kg/m2) 27·8 5·0 27·9 4·7 27·7 5·0 27·9 4·7 29·0 5·3 26·4 3·5
BMI at the end of the study (kg/m2) 28·0 5·0 28·0 4·8 27·9 5·0 28·0 4·8 29·3 5·5 26·6 3·4
Serum Ca at baseline (mmol/l) 2·27 0·07 2·27 0·70 2·27 0·07 2·27 0·07 2·28 0·07 2·29 0·09
Serum Ca at the end of the study (mmol/l) 2·29** 0·08 2·27 0·07 2·29** 0·08 2·27 0·07 2·27 0·07 2·25 0·07
Serum PTH at baseline (pmol/l) 6·7 2·2 6·8 1·9 6·6 2·1 6·8 1·9 7·2 2·6 6·2 1·1
Serum PTH at the end of the study (pmol/l) 5·9*** 2·0 7·3 2·2 5·9*** 1·9 7·3 2·2 6·5 2·2 7·0 1·4
Serum 25(OH)D at baseline (nmol/l) 32·5 11·1 35·1 13·6 32·8 11·2 35·4 13·7 28·3 9·0 29·8 11·0
Serum 25(OH)D at the end of the study (nmol/l) 88·8*** 19·5 30·7 9·7 89·3*** 18·8 30·8 9·8 82·2*** 27·3 28·1 8·0
BDI-II score at baseline† 4·0 0–25 4·0 0–23 4·0 0–25 4·0 0–22 10·5 1–21 14·0 4–23
BDI-II score at the end of the study† 2·0 0–27 2·0 0– 2 2·0 0–27 2·0 0–32 5·5 0–15 9·0 1–27
Change in BDI-II score −1·5 4·3 −1·9 4·1 −1·4 4·3 −1·9 4·1 −2·8 3·3 −2·6 4·7
PTH, parathyroid hormone; 25(OH)D, 25-hydroxyvitamin D; BDI-II, Beck Depression Inventory-II.
Mean value was significantly different from that of the corresponding placebo group: ** P < 0·01, *** P < 0·001 (linear regression with baseline value, age and sex as covariates).
†Medians and ranges.




























































































































168 subjects in the placebo group had baseline and final serum
25(OH)D < 50 nmol/l. Among these, thirty-nine subjects (of
whom eight were using anti-depressant medication) had a
baseline BDI-II score >13 and could thus be classified as
being mildly or more depressed. Thus, the ideal study group,
depressed, vitamin D-insufficient subjects, was therefore
rather small. However, no trend in favour of an effect of vita-
min D supplementation was seen, nor when restricting the
inclusion to subjects with even lower baseline serum 25(OH)
D levels.
We have previously published the cross-sectional relation-
ship between serum 25(OH)D and depressive symptoms
(evaluated by the Hopkins Symptoms Check List 10) from
the sixth survey in the Tromsø Study with more than 12 000
subjects included in the analyses(8). Although there was a
highly significant relationship, the difference in serum 25
(OH)D between those who were in the highest depression
score quartile v. those in the lowest was only about 6 %.
Accordingly, even if there is a causal relationship between
serum 25(OH)D and depression, it is unlikely that vitamin
D is of major importance. It also follows that a large number
of subjects need to be included to demonstrate an effect, espe-
cially if those included only have minor depressive symptoms.
In subjects with severe depressive symptoms, it might also
be unethical to try treatment with vitamin D alone, even if
the subjects are vitamin D insufficient. In clinical trials recruit-
ing such patients, vitamin D would appear to be more suited
as an add-on treatment(15).
As discussed above, our study has weaknesses, in particular
since most of our subjects were not clinically depressed. We
did not perform a formal power calculation before the start
of the study. However, a post hoc calculation (that as such
should be viewed with caution) indicated that we should
have had power to detect a difference in Δ BDI-II score of
1·2 between the two groups. Thus, we should have been
able to detect any clinically meaningful effect of the supple-
mentation. As we did eleven subgroup analyses the statistical
power of these analyses was considerably reduced, and the
subgroup analyses should be considered as exploratory only.
We used weekly vitamin D supplementation, and daily doses
may be more efficient if the serum level of unhydroxylated
vitamin D (cholecalciferol) is important(30). It has been
reported that the relationship between vitamin D and depres-
sive symptoms is only seen during the summer months(31).
This may indicate that vitamin D-independent effects of
sunlight may be drivers for the association between 25(OH)
D and depression, or perhaps that the relationship is depend-
ent upon serum level of vitamin D (cholecalciferol), that pre-
sumably is very low during the winter, and not 25(OH)D(30).
Furthermore, many of our subjects were included during the
winter months and therefore came to the final visit during
early spring. If season is important and depression less pro-
nounced in the spring, that may also have masked effects of
the vitamin D supplementation. We also used only one depres-
sion score instrument, which may not have picked up more
subtle changes. Also, finally, our study only lasted 4 months,
and we cannot exclude that to see an effect of vitamin D a
longer intervention period is needed. On the other hand,
our study does have strength and importance as it demon-
strates the futility of searching for vitamin D effects on depres-
sion in cohorts where the depression score is low, even in
vitamin D insufficiency.
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Table 3. Change in Beck Depression Inventory-II (Δ BDI-II) scores (score at the end of the study minus score at baseline) in relation to baseline and final
serum 25-hydroxyvitamin D (25(OH)D) levels and baseline BDI-II scores*
(Mean values and standard deviations)
Vitamin D group Placebo group
Δ BDI-II score Δ BDI-II score
n Mean SD n Mean SD
All subjects regardless of baseline and final 25(OH)D levels
Regardless of baseline BDI-II score 208 −1·5 4·3 202 −1·9 4·1
Baseline BDI-II score >4 100 −3·2 5·2 93 −3·8 5·0
Baseline BDI-II score >10 18 −7·1 5·5 27 −4·9 7·4
Subjects with baseline 25(OH)D < 50 nmol/l, and final 25(OH)D >70 nmol/l in the vitamin D group and final 25(OH)D <50 nmol/l in the placebo group
Regardless of baseline BDI-II score 163 −1·4 4·4 165 −2·0 4·3
Baseline BDI-II score >4 76 −3·1 5·5 76 −4·0 5·2
Baseline BDI-II score >10 15 −6·6 5·5 24 −5·1 7·4
Subjects with baseline 25(OH)D < 40 nmol/l, and final 25(OH)D > 70 nmol/l in the vitamin D group and final 25(OH)D < 40 nmol/l in the placebo group
Regardless of baseline BDI-II score 136 −1·9 4·2 126 −2·4 4·2
Baseline BDI-II score > 4 66 −3·8 5·0 57 −4·7 4·9
Baseline BDI-II score > 10 14 −7·1 5·4 17 −6·4 6·4
Subjects with baseline 25(OH)D < 30 nmol/l, and final 25(OH)D > 70 nmol/l in the vitamin D group and final 25(OH)D < 30 nmol/l in the placebo group
Regardless of baseline BDI-II score 74 −1·3 3·6 52 −2·0 4·5
Baseline BDI-II score >4 36 −2·6 4·6 23 −4·4 5·1
Baseline BDI-II score >10 7 −5·4 2·5 7 −6·7 5·4
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